Document › Details

Affimed N.V.. (5/22/19). "Press Release: Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio, Reports First Quarter 2019 Financial Results and Operational Progress". Heidelberg.

Organisations Organisation Affimed N.V. (Nasdaq: AFMD)
  Group Affimed (Group)
  Organisation 2 Genentech Inc.
  Group Roche (Group)
Products Product AFM11 (Affimed)
  Product 2 AFM13 (Affimed)
Persons Person Hoess, Adi (Affimed 201109– CEO before CCO before Jenowis + Jerini 2003– + Carl Zeiss AG + MorphoSys AG)
  Person 2 Gin, Gregory (Affimed 201808 Head of Investor Relations)
     


   
Record changed: 2019-05-31

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px

More documents for Affimed (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x113px




» top